Cypress Capital’s Avita Medical RCEL Stock Holding History

Cypress Capital’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10	Closed	-$79	–	290
2024 Q2	$79	Buy	+10	New	+$95	﹤0.01%	379

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cypress Capital's RCEL Position: Q3 2024 in Review

Cypress Capital sold out of Avita Medical (RCEL) in Q3 2024, closing a stake of 10 shares — an estimated $79 sold.

Cypress Capital first reported a position in RCEL in Q2 2024 and held it in 1 quarter. The position peaked at $79 in Q2 2024. 67 funds tracked by Wall St. Rank hold RCEL as of Q3 2024.

Cypress Capital reported no remaining Avita Medical position as of Q3 2024 after selling out during the quarter.
Cypress Capital sold 10 Avita Medical shares in Q3 2024, an estimated $79.
Cypress Capital first reported a position in Avita Medical in Q2 2024 and held it in 1 quarter.
Cypress Capital's Avita Medical position peaked at $79 in Q2 2024.
67 funds tracked by Wall St. Rank held Avita Medical as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.